I. Exhibition Overview
Octobris 8th, in MMXXIV CPHI worldwide pharmaceutical se ferre calce off in Mediolanum. Sicut unum ex maxime momenti annua certe in global pharmaceutical industria, quod attracted participantium ex CLXVI terris et regiones. Cum in 2,400 exhibitors et 62,000 professional attendees, in se ferre operuit 160,000 quadratum metris. Per eventu, magis quam C conferences et fora tenuit, alloquens variis topics vndique a pharmaceutical ordinationes et innovative medicamento progressionem ad Biopharmaceuticals et sustineri progressionem.
II. Jymmed scriptor ornare ipsum
Shenzhen JYMed Technology Co., Ltd. (hereinafter referred to as “JYMed”), as one of the largest peptide manufacturers in China, presented new technologies, products, and collaboration opportunities to global customers at the Milan exhibition. Per eventu, in jymmed dolor versantur in in-profundum disputationibus cum pharmaceutical turmas et clients ex circum orbem terrarum, sharing insights in key exitibus in peptide industria et offering valuable ideas et suasiones ad industria et in futurum progressionem.
Jymmed iactat an International Platform pro investigationis et productionem de peptides, peptide, sicut componit, et peptide, medicamento conjugatibus (PDCS). In comitatu tenet peritia in complexu peptide synthesis, core peptide chemica, et magnis scale productio technologiae. Hoc statutum diu terminus opportuna partnerships cum numerosis inclyta global conatibus. Jymed credit quod per resource sharing et complementary vires, potest addere magis spes et options ad aegros terrarum.
III. Pre se ferre summary
Duectus ab philosophia de "peptides ad meliorem futurum," jugum et continue driving pharmaceutical innovation et contribuens ad salutem et bene esse aegris circa mundum. Expectamus ad opus cum global peers ad amplectendum clara futura ad pharmaceutical industria.
De jymmed
Shenzhen jymmed technology Co., Ltd. (Hereñafter referred to as jmed) in statutum est in MMIX, specialiter in investigationis, progressionem, productio et venditionesque peptides et peptide actis products. Et unum investigationis centrum et tres major productionem bases, jymmed est unus de maxima effectrix chemica synthesized peptide apis in Sinis. In Company scriptor core R & D quadrigis quatenus super XX annos experientia in peptide industria et feliciter Transierunt FDA inspectionibus bis. Jymmed scriptor comprehensive et efficens peptide industrialization ratio praebet customers a plena range of muneris, comprehendo ad progressionem et productionem therapeutic peptides, VETERINARIUS peptides, antimicrobial peptides, et regulatory peptides, tum adnotatione et regulatory Support.
Pelagus res actiones
I. domesticis et internationalis adnotatione peptide apis
II. VETERINARIUS et COLOR peptides
III. Cro Custom Peptides et CRO, CMO, OEM Services
IV. PDC medicinae (peptide-radionuclide, peptide-parva moleculo, peptide, dapibus, peptide-rna)
Insuper et Tirzepatide, Jymed est Submitted Registration Fiction cum FDA et Cde pro pluribus aliis API products, comprehendo in currently popularibus GLP-1ra classis ut semaglutide et Liraglutide. Future customers per jymmed scriptor products poterit ad directe referat ad Cde adnotatione numero vel DMF file numerus cum submittendo adnotatione applications ad FDA aut Cde. Hoc autem significantly reducere tempus requiritur ad parat application documenta, tum iudicium et tempus et sumptus of productum recensionem.
Contact Us
Shenzhen jymmed technology Co., Ltd.
Oratio:8th & 9th contignationibus, aedificationem I, Shenzhen biomedical innovation Industrial Park, No. XIV Jinhui Road, Kengzi subdristic, Pingshan regio, Shenzhen
Phone:LXXXVI 755-26612112
Website: http://www.jymedtech.com/
Post tempus: Oct-18-2024
